Swedish Orphan Biovitrum (SOBI.ST)

Executive Summary

Swedish Orphan Biovitrum (Sobi) is a publicly traded biopharmaceutical company focused on rare diseases, with a strong commercial portfolio of five approved products, including therapies for hemophilia. The company's pipeline includes several late-stage assets: pacritinib in Phase 3 for myelofibrosis (completion expected 2027) and avatrombopag in Phase 2 for chemotherapy-induced thrombocytopenia (completion July 2026). At its Capital Markets Day in February 2026, Sobi outlined growth strategies, emphasizing pipeline advancement and expanded patient access. Financially, the company reported Q4 and FY2025 results in February 2026, with a market valuation of ~138 billion SEK. Sobi's commitment to innovation in rare diseases positions it well for long-term growth, supported by a robust pipeline and commercial execution.

Upcoming Catalysts (preview)

• Q3 2026Avatrombopag Phase 2 data in chemotherapy-induced thrombocytopenia70% success
• Q4 2026Pacritinib Phase 3 interim analysis in myelofibrosis60% success
• TBDPotential regulatory update for SOBI003 in Sanfilippo syndrome Type A30% success